Recce Pharmaceuticals (ASX:RCE) was granted a Family 4 patent by the Hong Kong Special Administrative Region for its anti-infectives, according to a Thursday Australian bourse filing.

The patent, expiring in 2041, relates to the process for preparation of the anti-infectives, as well as the use of its R327 and R529 therapy candidates, particularly in the treatment of bacterial infections and viral infections.

It also relates to the administration of the anti-infectives by oral, inhalation, transdermal delivery, or by injection. They can also be delivered as an aerosol, gel, topical foam, or ointment.

The firm's shares jumped 6% in recent trading on Thursday.